

# Pierre Amarenco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4235447/publications.pdf>

Version: 2024-02-01

118  
papers

16,311  
citations

61945

43  
h-index

23514

111  
g-index

119  
all docs

119  
docs citations

119  
times ranked

14495  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of non-stenotic carotid atherosclerotic plaques with combined FDG-PET imaging and CT angiography in patients with ischemic stroke of unknown origin. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1329-1336.	1.4	5
2	Intracranial Hemorrhage in the TST Trial. <i>Stroke</i> , 2022, 53, 457-462.	1.0	14
3	Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. <i>Neurology</i> , 2022, 99, .	1.5	7
4	Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke. <i>JAMA Neurology</i> , 2021, 78, 177.	4.5	17
5	Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations. <i>Neurology</i> , 2021, 96, e54-e66.	1.5	15
6	Temporary application of lower body positive pressure improves intracranial velocities in symptomatic acute carotid occlusion or tight stenosis: A pilot study. <i>International Journal of Stroke</i> , 2021, , 174749302110080.	2.9	1
7	Impact of Lower Versus Higher LDL Cholesterol Targets on Cardiovascular Events After Ischemic Stroke in Patients With Diabetes. <i>Diabetes</i> , 2021, 70, 1807-1815.	0.3	0
8	Indications de l'occlusion de l'auricule gauche comme substitut à l'anticoagulation chez les patients qui ont un AVC lié à une fibrillation atriale: le registre WATCH-AF. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2021, 205, 619-630.	0.0	0
9	Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2021, 52, 3482-3489.	1.0	9
10	Vascular origin in acute transient visual disturbance: A prospective study. <i>European Journal of Neurology</i> , 2021, 28, 4098-4108.	1.7	0
11	Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke. <i>JAMA Neurology</i> , 2021, 78, 1091.	4.5	11
12	High-Density Lipoprotein Therapy in Stroke: Evaluation of Endothelial SR-BI-Dependent Neuroprotective Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 106.	1.8	18
13	A Prospective, Observational Study of Rivaroxaban For Stroke Prevention In Atrial Fibrillation â€“ The XANAP Korea. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 906-913.	0.7	2
14	Minor Ischemic Stroke and a Smoldering Case of Giant-Cell Arteritis: A Case Report. <i>Stroke</i> , 2021, 52, e749-e752.	1.0	3
15	A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPIRE-TMS): an open-label, randomised controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 49-60.	4.9	69
16	A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. <i>New England Journal of Medicine</i> , 2020, 382, 9-19.	13.9	339
17	Impact of gender: Rivaroxaban for patients with atrial fibrillation in the <sc>XANTUS</sc> real-world prospective study. <i>Clinical Cardiology</i> , 2020, 43, 1405-1413.	0.7	2
18	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104936.	0.7	17

#	ARTICLE	IF	CITATIONS
19	Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. <i>New England Journal of Medicine</i> , 2020, 383, 207-217.	13.9	333
20	Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2355-2363.	1.0	3
21	Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. <i>Stroke</i> , 2020, 51, 3504-3513.	1.0	67
22	Changes in High-Density Lipoproteins Related to Outcomes in Patients with Acute Stroke. <i>Journal of Clinical Medicine</i> , 2020, 9, 2269.	1.0	12
23	Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial. <i>Clinical Trials</i> , 2020, 17, 617-626.	0.7	12
24	Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies. <i>Journal of Clinical Medicine</i> , 2020, 9, 4028.	1.0	2
25	Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2020, 382, 1933-1941.	13.9	49
26	Protective Effect of ApoA1 (Apolipoprotein A1)-Milano in a Rat Model of Large Vessel Occlusion Stroke. <i>Stroke</i> , 2020, 51, 1886-1890.	1.0	10
27	Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin. <i>Circulation</i> , 2020, 142, 748-757.	1.6	21
28	Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke. <i>Stroke</i> , 2020, 51, 1231-1239.	1.0	39
29	Aortic Sources of Embolism. <i>Frontiers in Neurology</i> , 2020, 11, 606663.	1.1	18
30	Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial. <i>Clinical Trials</i> , 2020, 17, 430-436.	0.7	2
31	Importance du cholest�rol et de son traitement dans la pr�vention de lâ€™AVC. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2020, 204, 283-291.	0.0	0
32	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. <i>Europace</i> , 2019, 21, 421-427.	0.7	10
33	Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019, 50, 2477-2485.	1.0	72
34	Disability after minor stroke and TIA. <i>Neurology</i> , 2019, 93, e708-e716.	1.5	36
35	Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials. <i>Stroke</i> , 2019, 50, 2187-2196.	1.0	13
36	International Collaborations Are Essential for Stroke. <i>Stroke</i> , 2019, 50, 2993-2994.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2019, 50, 3184-3190.	1.0	78
38	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	2.7	104
39	Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. <i>International Journal of Stroke</i> , 2019, 14, 908-914.	2.9	6
40	Non-cardioembolic stroke/transient ischaemic attack in Asians and non-Asians: A post-hoc analysis of the PERFORM study. <i>European Stroke Journal</i> , 2019, 4, 65-74.	2.7	17
41	Acute dual antiplatelet therapy for minor ischaemic stroke or transient ischaemic attack. <i>BMJ: British Medical Journal</i> , 2019, 364, l895.	2.4	21
42	Treat stroke to target trial design: First trial comparing two LDL targets in patients with atherothrombotic strokes. <i>European Stroke Journal</i> , 2019, 4, 271-280.	2.7	16
43	Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. <i>Stroke</i> , 2019, 50, 675-682.	1.0	3
44	The Acute Stroke or Transient Ischaemic Attack Treated with Ticagrelor or Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design. <i>International Journal of Stroke</i> , 2019, 14, 745-751.	2.9	28
45	Twelve-month outcome in patients with stroke and atrial fibrillation not suitable to oral anticoagulant strategy: the WATCH-AF registry. <i>Open Heart</i> , 2019, 6, e001187.	0.9	6
46	Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 70-79.	1.4	29
47	Risque 3 Mois, 1 An et 5 Ans des accidents ischémiques transitoires et infarctus cérébraux mineurs dans une cohorte contemporaine, multicentrique, multinationale, multicontinentale de 4879 patients. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2019, 203, 315-320.	0.0	0
48	Learning from TARDIS: time for more focused trials in stroke prevention. <i>Lancet, The</i> , 2018, 391, 819-821.	6.3	1
49	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	1.0	13
50	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. <i>Europace</i> , 2018, 20, e87-e95.	0.7	13
51	Intérêt de développer des cliniques d'AIT en France : est-ce utile pour la santé publique ?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 275-282.	0.0	0
52	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018, 206, 80-93.	1.2	276
53	Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. <i>New England Journal of Medicine</i> , 2018, 379, 1579-1581.	13.9	16
54	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 378, 2191-2201.	13.9	730

#	ARTICLE	IF	CITATIONS
55	Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. <i>New England Journal of Medicine</i> , 2018, 378, 2182-2190.	13.9	238
56	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018, 72, 141-153.	1.2	48
57	Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. <i>Stroke</i> , 2018, 49, 1678-1685.	1.0	20
58	Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 301-310.	4.9	174
59	Aspirin's Benefits Were Previously Underestimated and Are Primarily Accrued in the Acute Setting. <i>Stroke</i> , 2017, 48, 1438-1440.	1.0	1
60	Clinical Significance of Isolated Atypical Transient Symptoms in a Cohort With Transient Ischemic Attack. <i>Stroke</i> , 2017, 48, 1495-1500.	1.0	21
61	Differences in Characteristics and Outcomes Between Asian and Non-Asian Patients in the TIAregistry.org. <i>Stroke</i> , 2017, 48, 1779-1787.	1.0	18
62	Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting. <i>Stroke</i> , 2017, 48, 1005-1010.	1.0	13
63	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. <i>New England Journal of Medicine</i> , 2017, 376, 1517-1526.	13.9	307
64	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
65	Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2017, 48, 2480-2487.	1.0	19
66	Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks. <i>Stroke</i> , 2017, 48, 3223-3231.	1.0	28
67	Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic) <i>Tj ETQq1 1 0.7843142rgBT /Ov</i>	1.0	1
68	P3592 Safety analysis of rivaroxaban: a pooled analysis of the global XANTUS programme (real-world,) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i> <i>European Heart Journal</i> , 2017, 38, .	1.0	1
69	P300 Impact of gender: rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study. <i>Europace</i> , 2017, 19, iii46-iii47.	0.7	0
70	<sc>close</sc>: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design. <i>International Journal of Stroke</i> , 2016, 11, 724-732.	2.9	12
71	One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. <i>New England Journal of Medicine</i> , 2016, 374, 1533-1542.	13.9	444
72	Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2016, 375, 35-43.	13.9	424

#	ARTICLE	IF	CITATIONS
73	Dysfunctional HDL in acute stroke. <i>Atherosclerosis</i> , 2016, 253, 75-80.	0.4	34
74	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUSâ€œACTS Substudy. <i>Clinical Cardiology</i> , 2016, 39, 565-569.	0.7	33
75	Coronary and Basilar Artery Ectasia Are Associated. <i>Stroke</i> , 2016, 47, 224-227.	1.0	24
76	Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1045-1052.	1.0	9
77	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1145-1153.	1.0	383
78	Cyclosporine in acute ischemic stroke. <i>Neurology</i> , 2015, 84, 2216-2223.	1.5	49
79	Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (Socrates) Trial: Rationale and Design. <i>International Journal of Stroke</i> , 2015, 10, 1304-1308.	2.9	28
80	Pathophysiology, presentation, prognosis, and management of intracranial arterial dolichoectasia. <i>Lancet Neurology</i> , The, 2015, 14, 833-845.	4.9	119
81	Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke. <i>Stroke</i> , 2015, 46, 3241-3248.	1.0	153
82	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014, 10, 425.	1.0	29
83	Rupture of Nonstenotic Carotid Plaque as a Cause of Ischemic Stroke Evidenced by Multimodality Imaging. <i>Circulation</i> , 2014, 129, 130-131.	1.6	15
84	Low Levels of Low-Density Lipoprotein-C Associated With Proprotein Convertase Subtilisin Kexin 9 Inhibition Do Not Increase the Risk of Hemorrhagic Transformation. <i>Stroke</i> , 2014, 45, 3086-3088.	1.0	14
85	Impact of Diffusion-Weighted Imaging Alberta Stroke Program Early Computed Tomography Score on the Success of Endovascular Reperfusion Therapy. <i>Stroke</i> , 2014, 45, 1992-1998.	1.0	41
86	Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial. <i>Stroke</i> , 2014, 45, 2974-2982.	1.0	29
87	Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques. <i>Stroke</i> , 2014, 45, 1248-1257.	1.0	178
88	Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke. <i>Neurology</i> , 2014, 82, 1905-1913.	1.5	37
89	HDL-C, triglycerides and carotid IMT: A meta-analysis of 21,000 patients with automated edge detection IMT measurement. <i>Atherosclerosis</i> , 2014, 232, 65-71.	0.4	41
90	The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping). <i>Cerebrovascular Diseases</i> , 2013, 36, 1-5.	0.8	281

#	ARTICLE	IF	CITATIONS
91	Demographics, Socio-Economic Characteristics, and Risk Factor Prevalence in Patients with Non-Cardioembolic Ischaemic Stroke in Low- and Middle-Income Countries: The OPTIC Registry. <i>International Journal of Stroke</i> , 2013, 8, 4-13.	2.9	19
92	High-Density Lipoproteins Limit Neutrophil-Induced Damage to the Blood–Brain Barrier <i>in Vitro</i> . <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 575-582.	2.4	39
93	Overlap of Diseases Underlying Ischemic Stroke. <i>Stroke</i> , 2013, 44, 2427-2433.	1.0	42
94	High-density Lipoprotein–based Therapy Reduces the Hemorrhagic Complications Associated With Tissue Plasminogen Activator Treatment in Experimental Stroke. <i>Stroke</i> , 2013, 44, 699-707.	1.0	33
95	Mannheim Carotid Intima-Media Thickness and Plaque Consensus (2004–2006–2011). <i>Cerebrovascular Diseases</i> , 2012, 34, 290-296.	0.8	1,235
96	Risk of Stroke and Cardiovascular Events After Ischemic Stroke or Transient Ischemic Attack in Patients With Type 2 Diabetes or Metabolic Syndrome. <i>Archives of Neurology</i> , 2011, 68, 1245.	4.9	91
97	Prevalence of Coronary Atherosclerosis in Patients With Cerebral Infarction. <i>Stroke</i> , 2011, 42, 22-29.	1.0	150
98	Coronary Heart Disease Risk in Patients With Stroke or Transient Ischemic Attack and No Known Coronary Heart Disease. <i>Stroke</i> , 2010, 41, 426-430.	1.0	47
99	Protective Effect of High-Density Lipoprotein-Based Therapy in a Model of Embolic Stroke. <i>Stroke</i> , 2010, 41, 1536-1542.	1.0	50
100	Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. <i>Lancet Neurology</i> , The, 2009, 8, 453-463.	4.9	537
101	Underlying Pathology of Stroke of Unknown Cause (Cryptogenic Stroke). <i>Cerebrovascular Diseases</i> , 2009, 27, 97-103.	0.8	61
102	Classification of Stroke Subtypes. <i>Cerebrovascular Diseases</i> , 2009, 27, 493-501.	0.8	350
103	Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. <i>Atherosclerosis</i> , 2009, 204, 515-520.	0.4	81
104	Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. <i>Neurology</i> , 2008, 70, 2364-2370.	1.5	372
105	Atorvastatin Reduces the Risk of Cardiovascular Events in Patients With Carotid Atherosclerosis. <i>Stroke</i> , 2008, 39, 3297-3302.	1.0	243
106	Stroke and Vascular Mortality Trends in France: 1979–2001. <i>Neuroepidemiology</i> , 2007, 29, 78-82.	1.1	7
107	Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2007, 38, 3198-3204.	1.0	302
108	Correlation between the Framingham risk score and intima media thickness: The Paroi Artérielle et Risque Cardio-vasculaire (PARC) study. <i>Atherosclerosis</i> , 2007, 192, 363-369.	0.4	54

#	ARTICLE	IF	CITATIONS
109	The paradox of cholesterol and stroke. <i>Lancet</i> , The, 2007, 370, 1803-1804.	6.3	32
110	Telemedicine for Improving Emergent Management of Acute Cerebrovascular Syndromes. <i>International Journal of Stroke</i> , 2007, 2, 47-50.	2.9	19
111	A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. <i>Lancet Neurology</i> , The, 2007, 6, 953-960.	4.9	602
112	High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2006, 355, 549-559.	13.9	2,497
113	Carotid Intima-Media Thickness, Plaques, and Framingham Risk Score as Independent Determinants of Stroke Risk. <i>Stroke</i> , 2005, 36, 1741-1745.	1.0	172
114	Statins in Stroke Prevention and Carotid Atherosclerosis. <i>Stroke</i> , 2004, 35, 2902-2909.	1.0	686
115	Characterization of Polymorphic Structure of Cathepsin G Gene. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1538-1543.	1.1	33
116	Atherosclerotic Disease of the Aortic Arch as a Risk Factor for Recurrent Ischemic Stroke. <i>New England Journal of Medicine</i> , 1996, 334, 1216-1221.	13.9	640
117	Atherosclerotic Disease of the Aortic Arch and the Risk of Ischemic Stroke. <i>New England Journal of Medicine</i> , 1994, 331, 1474-1479.	13.9	971
118	The Prevalence of Ulcerated Plaques in the Aortic Arch in Patients with Stroke. <i>New England Journal of Medicine</i> , 1992, 326, 221-225.	13.9	557